title

抗体薬物複合体「DS-3939」　固形がん患者P1/2試験データ公表　第一三共 | 医薬通信社

charset

utf-8

X-UA-Compatible

IE=edge

HandheldFriendly

True

MobileOptimized

320

og:type

article

og:description

第一三共は20日、開発中の「DS-3939」（抗TA-MUC1抗体薬物複合体）について、P1/2試験の用量漸増パートデータを欧州臨床腫瘍学会（ESMO 2025）で公表したことを明らかにした。　同剤は、抗TA-MUC1抗体を基盤とし、第一三...

og:title

抗体薬物複合体「DS-3939」　固形がん患者P1/2試験データ公表　第一三共

og:url

https://iyakutsushinsha.com/2025/10/20/%e6%8a%97%e4%bd%93%e8%96%ac%e7%89%a9%e8%a4%87%e5%90%88%e4%bd%93%e3%80%8cds-3939%e3%80%8d%e3%80%80%e5%9b%ba%e5%bd%a2%e3%81%8c%e3%82%93%e6%82%a3%e8%80%85p1-2%e8%a9%a6%e9%a8%93%e3%83%87%e3%83%bc%e3%82%bf/

og:image

https://iyakutsushinsha.com/wp-content/uploads/2025/10/fd4a98ec0e04602a8e3556b8af0c9ab6.jpg

twitter:card

summary_large_image

twitter:image

https://iyakutsushinsha.com/wp-content/uploads/2025/10/fd4a98ec0e04602a8e3556b8af0c9ab6.jpg

twitter:domain

iyakutsushinsha.com

url

https://iyakutsushinsha.com/wp-content/themes/cocoon-master/images/no-amp-logo.png

width

206

height

60

position

1

position

2

alternate

https://iyakutsushinsha.com/feed/

alternate

https://iyakutsushinsha.com/comments/feed/

alternate

https://iyakutsushinsha.com/2025/10/20/%e6%8a%97%e4%bd%93%e8%96%ac%e7%89%a9%e8%a4%87%e5%90%88%e4%bd%93%e3%80%8cds-3939%e3%80%8d%e3%80%80%e5%9b%ba%e5%bd%a2%e3%81%8c%e3%82%93%e6%82%a3%e8%80%85p1-2%e8%a9%a6%e9%a8%93%e3%83%87%e3%83%bc%e3%82%bf/feed/

apple-touch-icon

https://iyakutsushinsha.com/wp-content/uploads/2019/06/cropped-site-logo-180x180.jpg

canonical

https://iyakutsushinsha.com/2025/10/20/%e6%8a%97%e4%bd%93%e8%96%ac%e7%89%a9%e8%a4%87%e5%90%88%e4%bd%93%e3%80%8cds-3939%e3%80%8d%e3%80%80%e5%9b%ba%e5%bd%a2%e3%81%8c%e3%82%93%e6%82%a3%e8%80%85p1-2%e8%a9%a6%e9%a8%93%e3%83%87%e3%83%bc%e3%82%bf/